FDA Says Chembio's HIV Test is Approvable
Posted on: Thursday, 20 April 2006, 12:00 CDT
Chembio Diagnostics has received an approvable letter from the FDA for its rapid test for HIV.
The FDA letter states that approval is subject only to final review by the FDA of the package inserts for each of the products, a review which has been ongoing, and other standard conditions.
Chembio said that it anticipates final approval in the very near future allowing the company to market its tests to clinical laboratories and hospitals in the United States.
"I am pleased that our development efforts, now fully supported by the FDA review of our clinical data and inspection of our facility, have brought us within clear sight of the goal of approval. Rapid tests allow greater access to testing, which results in more people being diagnosed earlier, when treatment is most effective," stated Javan Esfandiari, Chembio's vice president of research & development.
Source: Datamonitor
Related Articles
- U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
- ImClone and Bristol-Myers Squibb's Cancer Drug sBLA Wins FDA Priority Review
- Chairman of Citizens for Health Declares FDA Should Review Approval of Splenda
- FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
- FDA Blocks Trexima Approval Again
- Dendreon Says FDA to Review Provenge Submission
- FDA Grants Adeza Priority Review for Gestiva to Prevent Preterm Births; Goal of 6 Months Set By FDA to Review NDA for Gestiva
- FDA to Review Insmed's Complete Response to Approvable Letter for iPlex
- Forest Laboratories Inc. Says FDA Did Not Approve Its Drug to Treat Mild Alzheimer's
- FDA Orders Review of Studies of Prescription Painkillers
 |
 |
User Comments (0)
RSS Feeds